Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
about
Cytokine Signaling in Tumor Progression.Investigational Janus kinase inhibitors in development for myelofibrosis.The significance of Trk receptors in pancreatic cancer.A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.Precision therapy for acute myeloid leukemia.
P2860
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
@en
type
label
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
@en
prefLabel
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
@en
P2093
P2860
P1433
P1476
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
@en
P2093
Attilio Orazi
Crystal Miller
David Leibowitz
Elizabeth O Hexner
Ellen K Ritchie
Erin P Demakos
Gail J Roboz
Heike L Pahl
James Siuty
Jill Kleczko
P2860
P304
P356
10.3109/10428194.2014.1001986
P577
2015-01-07T00:00:00Z